Investors & Media International Stem Cell Corporation Partners with Absorption Systems to Commercialize Human Stem Cell-Derived Corneal Tissue for Drug Testing International Stem Cell Corporation Releases Letter to Shareholders International Stem Cell Corporation Retains The Investor Relations Group International Stem Cell Corporation Names Rouslan Semechkin to Board of Directors International Stem Cell Corporation Arranges $ 3 Million Equity Financing International Stem Cell Corporation and Novocell, Inc. Collaborate to Test Human Parthenogenetic Stem Cells for production of Pancreatic Islet Cells that may be useful in the Treatment of Diabetes International Stem Cell Corporation Announces Collaboration with Michigan State University to Study Parthenogenetic Stem Cells International Stem Cell Corporation Signs Agreement with BioTime, Inc., and Embryome Sciences, Inc., to Provide Unique Human Stem Cell Lines for Research Use International Stem Cell Corporation's Human Parthenogenetic Stem Cells to be used in the Development of Treatments for Liver Disease International Stem Cell Corporation Obtains Exclusive Rights in the US and Canada to Distribute Approved Human Skin Model for Toxicity Testing 26 27 28 29 30 31 32 33 34 35 << < > >>
